Protection and Promotion of Traditional Medicine - Implications for Public Health in Developing Countries
(2002; 131 pages) View the PDF document
Table of Contents
View the documentThe South Centre
View the documentPREFACE
View the documentINTRODUCTION
Open this folder and view contentsI. INTELLECTUAL PROPERTY AND TRM
Open this folder and view contentsII. RATIONALE FOR PROTECTION
Close this folderA. Patents
View the documentA.1. Novelty
View the documentA.2. Inventive step
Close this folderA.3. What can be patented?
View the document(i) Natural products
View the document(ii) Extracts and formulations
View the document(iii) Combinations and preparations
View the document(iv) Production and extraction processes
View the document(v) Methods for treatment and diagnostics
View the document(vi) Uses of known products
View the document(d) Patenting of TRM in practice
View the documentB. Trade Secrets
View the documentC. Trademarks
View the documentD. Geographical Indications
Open this folder and view contentsIV. POLICY OPTIONS: PROTECTING AND PROMOTING TRM
View the documentV. IPRs AND PUBLIC HEALTH
View the documentVI. CONCLUSIONS
View the documentREFERENCES
(v) Methods for treatment and diagnostics

Traditional treatment methods are usually specific to a particular country or to a particular community, although some of them, such as acupuncture, are used worldwide. Many methods of TRM have proven to be efficient and cost-effective in the provision of primary healthcare in the community, without causing harm to the human body. Such methods are generally accessible and affordable to people of all strata, particularly those living in poor and isolated regions (Ma’at, 2001, p. 2).

The patent protection of treatment and diagnostic methods faces important obstacles and limitations. First, such methods - which are applied to the human body - do not comply with the requirement of industrial applicability, imposed in most countries as a condition of patentability.110 A noticeable exception is the U.S., where “usefulness” and not industrial applicability is required, thereby broadening the room for such patenting to occur. Second, at least in the case of codified TRM, treatment methods, would be non patentable due to lack of novelty. Third, the enforcement of these kind of patents is problematic, since monitoring the use of treatments and prosecuting infringement is extremely difficult and costly.

110 In a few countries where this rule applies, the patentability of said methods has been allowed on the basis of courts’ interpretation or legal exceptions. See, e.g. Correa, 2000b, p. 26.

Most national patent laws exclude the patentability of diagnostic, therapeutic and surgical methods for the treatment of humans or animals, for legal, ethical or practical reasons. Article 27.3.a of the TRIPS Agreement explicitly allows Members not to grant patents for such methods. However, in the United States, patent practice increasingly favors the protection of medical methods, although a bill enacted in 1996 (amending US patent law, 35 USC 287.c) determined that the use of patented surgical methods can not be subjected to infringement suits.111. An illustration of such patents was the controversial (and finally revoked) US patent relating to turmeric mentioned above, which claimed a method of healing wounds and not the substance as such.

111 See, e.g. Grubb, 1999, p. 220.

In sum, because of their non-industrial applicability, or of their outright exclusion, treatment methods are generally not appropriable under patent laws. This means that TRM methods of treatment, whether codified or not, do not face the same risk of misappropriation by third parties as biological materials of medicinal use,112 being the U.S. - and a few other countries - a noticeable exception.

112 This also means, of course, that TRM holders will be unable to obtain patent protection over such methods.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017